Spotlight on Otolaryngology

Credits: 0.25 CME / MOC
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy
Peter A. Lio, MD, FAAD
Global Education Group

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Otolaryngology Presentations

0.75 CME / MOC
Vindico
Chronic Cough in Your Otolaryngology Practice: Current Challenges and Future Perspectives

Chronic Cough in Your Otolaryngology Practice: Current Challenges and Future Perspectives

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/ABOHNS MOC
Released: December 28, 2020
Expires: December 27, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is otolaryngologists and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden of chronic cough on patient quality of life.
  • Examine the latest mechanistic understanding regarding chronic cough from an otolaryngology perspective.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients with refractory chronic cough who may benefit from emerging therapies. In this educational activity, experts will discuss current unmet needs in chronic cough, underlying mechanisms from an otolaryngology perspective, and guidelines for assessment and management. Faculty will also review the latest data on emerging treatment strategies to improve the quality of life for patients with refractory chronic cough.

Agenda

Introduction – Kenneth W. Altman, MD, PhD, FACS
Current Guidelines and Unmet Needs in Chronic Cough – Jonathan M. Bock, MD, FACS
Pathophysiology of Chronic Cough – Kenneth W. Altman, MD, PhD, FACS
Emerging Options for Refractory Chronic Cough – Peter Dicpinigaitis, MD, FCCP
Key Takeaways and Conclusion – Kenneth W. Altman, MD, PhD, FACS

Activity Chair

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosure:
Consulting Fee: AXDEV



Faculty

Jonathan M. Bock, MD, FACS
Associate Professor, Division of Laryngology & Professional Voice
Department of Otolaryngology & Communication Sciences
Medical College of Wisconsin
Milwaukee, WI

Disclosure:
No relevant financial relationships to disclose.



Peter Dicpinigaitis, MD, FCCP
Professor of Medicine
Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosure:
Consulting Fee: Bayer, Bellus, Merck, Shionogi



Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

This enduring material is approved for 1 year from the date of original release, December 28, 2020 to December 27, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/ABOHNS MOC
Released: December 28, 2020
Expires: December 27, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is otolaryngologists and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden of chronic cough on patient quality of life.
  • Examine the latest mechanistic understanding regarding chronic cough from an otolaryngology perspective.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients with refractory chronic cough who may benefit from emerging therapies. In this educational activity, experts will discuss current unmet needs in chronic cough, underlying mechanisms from an otolaryngology perspective, and guidelines for assessment and management. Faculty will also review the latest data on emerging treatment strategies to improve the quality of life for patients with refractory chronic cough.

Agenda

Introduction – Kenneth W. Altman, MD, PhD, FACS
Current Guidelines and Unmet Needs in Chronic Cough – Jonathan M. Bock, MD, FACS
Pathophysiology of Chronic Cough – Kenneth W. Altman, MD, PhD, FACS
Emerging Options for Refractory Chronic Cough – Peter Dicpinigaitis, MD, FCCP
Key Takeaways and Conclusion – Kenneth W. Altman, MD, PhD, FACS

Activity Chair

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosure:
Consulting Fee: AXDEV



Faculty

Jonathan M. Bock, MD, FACS
Associate Professor, Division of Laryngology & Professional Voice
Department of Otolaryngology & Communication Sciences
Medical College of Wisconsin
Milwaukee, WI

Disclosure:
No relevant financial relationships to disclose.



Peter Dicpinigaitis, MD, FCCP
Professor of Medicine
Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosure:
Consulting Fee: Bayer, Bellus, Merck, Shionogi



Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

This enduring material is approved for 1 year from the date of original release, December 28, 2020 to December 27, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma and Atopic Dermatitis and Treatment-Related Conjunctivitis

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize adverse events related to biologics used to treat atopic diseases
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world atopic dermatitis patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Patient with Asthma Requiring Step-up Therapy

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: December 21, 2020
Expires: December 20, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
  • Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL


Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA


Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.